CONTEXT: Raloxifene is a promising breast cancer prevention agent in postmenopausal women at increased risk for breast cancer. The effects of raloxifene in premenopausal women are unknown. OBJECTIVE: We evaluated the effect of raloxifene in premenopausal women at increased risk for breast cancer on bone mineral density (BMD). DESIGN: This was a phase II clinical trial. SETTING: This study was conducted at an academic medical center. PARTICIPANTS: Thirty-seven premenopausal women at increased risk for breast cancer enrolled in the trial. Thirty subjects began treatment and 27 were evaluable. INTERVENTION: Raloxifene (60 mg daily) and elemental calcium (500 mg daily) were given for 2 yr. Subjects were followed up off medications for 1 yr. MAIN OUTCOME MEASURE: The primary end point was the intrasubject percent change in BMD at 1 yr measured by dual-energy x-ray absorptiometry. RESULTS: The mean baseline lumbar spine density was 1.027 g/cm(2). Lumbar spine density decreased 2.3% at 1 yr (P < 0.00001) and 3.5% at 2 yr (P < .00001). Percent change from yr 2 to 3 was +1.4%. The mean baseline total hip bone density was 0.905 g/cm(2). Total hip density decreased 0.3% at 1 yr and 1.0% at 2 yr (P = 0.033). Percent change from yr 2 to 3 was +1.7%. CONCLUSIONS: Raloxifene use is associated with a decrease in BMD in premenopausal women at increased risk for breast cancer. The clinical significance of this decrease is unknown and is attenuated with stopping raloxifene.
CONTEXT: Raloxifene is a promising breast cancer prevention agent in postmenopausal women at increased risk for breast cancer. The effects of raloxifene in premenopausal women are unknown. OBJECTIVE: We evaluated the effect of raloxifene in premenopausal women at increased risk for breast cancer on bone mineral density (BMD). DESIGN: This was a phase II clinical trial. SETTING: This study was conducted at an academic medical center. PARTICIPANTS: Thirty-seven premenopausal women at increased risk for breast cancer enrolled in the trial. Thirty subjects began treatment and 27 were evaluable. INTERVENTION: Raloxifene (60 mg daily) and elemental calcium (500 mg daily) were given for 2 yr. Subjects were followed up off medications for 1 yr. MAIN OUTCOME MEASURE: The primary end point was the intrasubject percent change in BMD at 1 yr measured by dual-energy x-ray absorptiometry. RESULTS: The mean baseline lumbar spine density was 1.027 g/cm(2). Lumbar spine density decreased 2.3% at 1 yr (P < 0.00001) and 3.5% at 2 yr (P < .00001). Percent change from yr 2 to 3 was +1.4%. The mean baseline total hip bone density was 0.905 g/cm(2). Total hip density decreased 0.3% at 1 yr and 1.0% at 2 yr (P = 0.033). Percent change from yr 2 to 3 was +1.7%. CONCLUSIONS:Raloxifene use is associated with a decrease in BMD in premenopausal women at increased risk for breast cancer. The clinical significance of this decrease is unknown and is attenuated with stopping raloxifene.
Authors: Jennifer Eng-Wong; Jennifer Orzano-Birgani; Catherine K Chow; David Venzon; Jianhua Yao; Claudia E Galbo; Jo Anne Zujewski; Sheila Prindiville Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-06-26 Impact factor: 4.254
Authors: Adi Cohen; Emily M Stein; Robert R Recker; Joan M Lappe; David W Dempster; Hua Zhou; Serge Cremers; Donald J McMahon; Thomas L Nickolas; Ralph Müller; Alexander Zwahlen; Polly Young; Julie Stubby; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2013-03-29 Impact factor: 5.958
Authors: Kala Visvanathan; Rowan T Chlebowski; Patricia Hurley; Nananda F Col; Mary Ropka; Deborah Collyar; Monica Morrow; Carolyn Runowicz; Kathleen I Pritchard; Karen Hagerty; Banu Arun; Judy Garber; Victor G Vogel; James L Wade; Powel Brown; Jack Cuzick; Barnett S Kramer; Scott M Lippman Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Julie R Gralow; J Sybil Biermann; Azeez Farooki; Monica N Fornier; Robert F Gagel; Rashmi N Kumar; Charles L Shapiro; Andrew Shields; Matthew R Smith; Sandy Srinivas; Catherine H Van Poznak Journal: J Natl Compr Canc Netw Date: 2009-06 Impact factor: 11.908
Authors: T W Weickert; D Weinberg; R Lenroot; S V Catts; R Wells; A Vercammen; M O'Donnell; C Galletly; D Liu; R Balzan; B Short; D Pellen; J Curtis; V J Carr; J Kulkarni; P R Schofield; C S Weickert Journal: Mol Psychiatry Date: 2015-05-18 Impact factor: 15.992
Authors: Davide Serrano; Matteo Lazzeroni; Sara Gandini; Debora Macis; Harriet Johansson; Jennifer Gjerde; Ernst Lien; Irene Feroce; Giancarlo Pruneri; Maria Sandri; Fabio Bassi; Fabricio Brenelli; Alberto Luini; Massimiliano Cazzaniga; Clara Varricchio; Aliana Guerrieri-Gonzaga; Andrea DeCensi; Bernardo Bonanni Journal: Breast Cancer Res Date: 2013-06-20 Impact factor: 6.466